A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

NCT00600275 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Breast Cancer
Cowden Syndrome

Interventions

DRUG: BGT226

Sponsor

Novartis Pharmaceuticals